ArticlePeerJ2025
BMP2 alterations in mucinous cystadenocarcinoma of the breast: insights from whole-exome sequencing.
Article in PeerJ, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular characterization of mammary mucinous cystadenocarcinoma reveals recurrent TP53 and RB1 alterations with frequent PI3K-AKT pathway abnormalities.Virchows Archiv : an international journal of pathology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucinous cystadenocarcinoma (MCA) of the breast is a rare and distinct type of mammary tract adenocarcinoma. Molecular alterations in breast MCA remain poorly characterized in current epidemiological data. Methods: We summarized the clinicopathological characteristics and performed exome sequencing on formalin-fixed, paraffin-embedded blocks from three patients with mammary MCA culled from the surgical pathology archives of Chongqing University Cancer Hospital. The tumor mutation landscape of these patients was determined using whole-exome sequencing. We assessed cancer effect sizes and analyzed the contribution of mutational processes to each oncogenic variant, quantifying the extent to which each process contributed to tumorigenesis/cancer effects. Results: Our analysis revealed that one of the three patient cohorts with advanced-stage breast MCA demonstrated aggressive clinical behavior, which contrasts with the typically reported indolent course of this rare malignancy. We also identified a significant mutant gene, bone morphogenetic protein 2 (BMP2), that is associated with breast MCA. Furthermore, we evaluated the expression by immunohistochemistry in patients with breast MCA and predicted the potential molecular functions of BMP2 in breast cancer through Conclusion: This study provides new insights into the clinical and molecular features of breast MCA, suggesting that tumor stage is an important prognostic indicator. BMP2 emerged as a potential driver of tumor progression, and its utility as a predictive or prognostic biomarker warrants further investigation in larger cohorts. These findings may pave the way for improved prognostic assessment and novel therapeutic strategies targeting BMP2 in breast MCA.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.